Noninvasive positive pressure ventilation (NPPV) devices are used during sleep to treat patients with diurnal chronic alveolar hypoventilation (CAH). Bilevel positive airway pressure (BPAP) using a mask interface is the most commonly used method to provide ventilatory support in these patients. BPAP devices deliver separately adjustable inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP). The IPAP and EPAP levels are adjusted to maintain upper airway patency, and the pressure support (PS = IPAP-EPAP) augments ventilation. NPPV devices can be used in the spontaneous mode (the patient cycles the device from EPAP to IPAP), the spontaneous timed (ST) mode (a backup rate is available to deliver IPAP for the set inspiratory time if the patient does not trigger an IPAP/EPAP cycle within a set time window), and the timed (T) mode (inspiratory time and respiratory rate are fixed). During NPPV titration with polysomnography (PSG), the pressure settings, backup rate, and inspiratory time (if applicable) are adjusted to maintain upper airway patency and support ventilation. However, there are no widely available guidelines for the titration of NPPV in the sleep center. A NPPV Titration Task Force of the American Academy of Sleep Medicine reviewed the available literature and developed recommendations based on consensus and published evidence when available. The major recommendations derived by this consensus process are as follows:
Summary:
Noninvasive positive pressure ventilation (NPPV) devices are used during sleep to treat patients with diurnal chronic alveolar hypoventilation (CAH). Bilevel positive airway pressure (BPAP) using a mask interface is the most commonly used method to provide ventilatory support in these patients. BPAP devices deliver separately adjustable inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP). The IPAP and EPAP levels are adjusted to maintain upper airway patency, and the pressure support (PS = IPAP-EPAP) augments ventilation. NPPV devices can be used in the spontaneous mode (the patient cycles the device from EPAP to IPAP), the spontaneous timed (ST) mode (a backup rate is available to deliver IPAP for the set inspiratory time if the patient does not trigger an IPAP/EPAP cycle within a set time window), and the timed (T) mode (inspiratory time and respiratory rate are fixed). During NPPV titration with polysomnography (PSG), the pressure settings, backup rate, and inspiratory time (if applicable) are adjusted to maintain upper airway patency and support ventilation. However, there are no widely available guidelines for the titration of NPPV in the sleep center. A NPPV Titration Task Force of the American Academy of Sleep Medicine reviewed the available literature and developed recommendations based on consensus and published evidence when available. The major recommendations derived by this consensus process are as follows:
General Recommendations:
1. The indications, goals of treatment, and side effects of NPPV treatment should be discussed in detail with the patient prior to the NPPV titration study. 2. Careful mask fitting and a period of acclimatization to low pressure prior to the titration should be included as part of the NPPV protocol. 3. NPPV titration with PSG is the recommended method to determine an effective level of nocturnal ventilatory support in patients with CAH. In circumstances in which NPPV treatment is initiated and adjusted empirically in the outpatient setting based on clinical judgment, a PSG should be utilized if possible to confirm that the final NPPV settings are effective or to make adjustments as necessary. 4 . NPPV treatment goals should be individualized but typically include prevention of worsening of hypoventilation during sleep, improvement in sleep quality, relief of nocturnal dyspnea, and providing respiratory muscle rest. 5. When OSA coexists with CAH, pressure settings for treatment of OSA may be determined during attended NPPV titration PSG following AASM Clinical Guidelines for the Manual Titration of Positive Airway Pressure in Patients with Obstructive Sleep Apnea . 6. Attended NPPV titration with PSG is the recommended method to identify optimal treatment pressure settings for patients with the obesity hypoventilation syndrome (OHS), CAH due to restrictive chest wall disease (RTCD), and acquired or central CAH syndromes in whom NPPV treatment is indicated. 7. Attended NPPV titration with PSG allows definitive identification of an adequate level of ventilatory support for patients with neuromuscular disease (NMD) in whom NPPV treatment is planned.
INTRODUCTION
Compelling evidence exists to support the use of noninvasive positive pressure ventilation (NPPV) via mask during sleep in the management of selected chronic alveolar hypoventilation (CAH) syndromes in adults and children. Improved sleep, nocturnal arterial oxygen saturation, diurnal and nocturnal arterial PCO 2 , and quality of life indicators have been ascribed to nocturnal respiratory assistance in a divergent spectrum of disorders. NPPV has been used in CAH syndromes secondary to central respiratory control disturbances (CRCD), restrictive thoracic cage disorders (RTCD), neuromuscular diseases (NMD), and the obesity hypoventilation syndrome (OHS). Application of NPPV via a mask interface avoids the morbidity involved with tracheostomy. The most common approach is delivery of bilevel positive airway pressure 47 (BPAP) in which separately adjustable inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP) are delivered. The pressure support mode devices are inherently leak tolerant and therefore ideal for use with mask ventilation.
Clinical Guidelines for the manual titration of positive airway pressure titration in patients with obstructive sleep apnea have recently been published regarding adjustment of CPAP and BPAP. 48 However, a standard approach to NPPV titration has not yet appeared in the published literature. Many sleep centers have limited experience in dealing with patients with CAH syndromes other than the obesity hypoventilation syndrome. Individual sleep centers that care for a large number of patients with CAH syndromes do have protocols. However, these are not widely available and may reflect a particular mix of patients (e.g., predominantly neuromuscular disease). Protocols for NPPV titration are available from individual NPPV device manufacturers but often contain device-specific recommendations. Recognizing the need for development of guidelines for NPPV titration using polysomnography (PSG), the AASM Board of Directors appointed the NPPV Titration Task Force to develop recommendations for NPPV titration during PSG in sleep centers. The goal of the NPPV Task Force was the development of evidence-and consensus-based standardized NPPV titration guidelines, with the underlying concept that a successful titration is one in which October 8, 2008 to discuss the Rand consensus process and to assign literature search topics to the committee members. A set of potential recommendations was developed to reflect the available evidence and NPPV titration protocols supplied by device manufacturers and several sleep centers with experience in NPPV titration. The proposed ballot was discussed during a second conference call on December 8, 2008 , and the task force members made recommendations for revisions. After compiling these revisions the first ballot was sent to task force members who then independently voted on the recommendations. For balloting, the possible recommendations were rated on a 9-point scale. The "classic" definition of agreement was assessed using definitions from the RAND manual: Agreement for or against: No more than 2 Task Force members rate the indication outside the 3-point region (1-3, 4-6, 7-9) containing the median. Disagreement: At least 3 Task Force members rate the indication in the 1-3 region, and at least 3 Task Force members rate it in the 7-9 region. Indeterminate: Criteria are not met for agreement or disagreement. A third conference call took place on Feb 27, 2009 , to review the tabulated balloting and discuss areas in which no consensus was reached. A second ballot for items that did not reach consensus was created and distributed to task force members in March 2008. A third conference call on May 28, 2009 , was convened to review the 2nd ballot results and reach consensus on the remaining items.
The recommendations in section 4.0 were developed based on the voting results. The nomenclature for the recommendations and levels of recommendation are listed in the Table 2 . The recommendations were reviewed by the Task Force members there is an optimized trade-off between increasing pressure to yield efficacy in supporting ventilation and decreasing pressure to minimize emergence of pressure-related side effects.
METHODS
The AASM Board of Directors approved the development of NPPV titration recommendations in October of 2007 and approved the appointments of Task Force members in February 2008. The mandate for the scope of the titration recommendations included CAH syndromes due to defects in CRCD, RTCD, NMD, and OHS. The use of NPPV in patients with chronic obstructive pulmonary disease (COPD) was not included in the Task Force's mandate, which also did not include establishing indications for NPPV treatment. A literature search was conducted using the key words: NPPV titration, mask ventilation, nasal ventilation, non-invasive positive pressure ventilation, kyphoscoliosis, NPPV treatment, bilevel positive airway pressure titration, bi-level pressure titration, BPAP titration, obesity hypoventilation syndrome, central hypoventilation, congenital central hypoventilation, neuromuscular disease (including ALS and muscular dystrophy), and BPAP adjustment. All literature searches were computer-based using PubMed. The objective was to identify all studies that described NPPV titration protocols and NPPV treatment of the disorders of interest. Additional publications were obtained by review of the bibliographies of the initial set of publications. The Task Force also reviewed NPPV titration protocols developed by industry for background information. However, these protocols were not used to support the final recommendations. All relevant publications were assigned an evidence level based on the classification 49 shown in Table 1 . Summaries of studies relevant to the titration of NPPV are located in the Appendix. (The Appendix is available online only at www.aasmnnet.org/jcsm.) The evidence grades listed indicate the level of evidence available to support the findings of the study. In most instances, studies were not designed to validate the NPPV titration protocol.
As high level evidence was lacking in most areas concerning NPPV titration, a consensus process was felt to be necessary in order to guide the process. The Rand/UCLA Appropriateness Method 50 was selected for this purpose given its use by the AASM Standards of Practice Committee (SPC) and the Clinical Guidelines for the titration of CPAP and BPAP Task Force. 48 The first conference call of the NPPV Task Force was held on umes (10-15 mL/kg) to compensate for leak. Today, the most common approach is to use a bilevel positive airway pressure (BPAP) device which delivers separately adjustable inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP). 47 The IPAP and EPAP are adjusted to maintain upper airway patency and the IPAP-EPAP difference provides pressure support (PS) to augment tidal volume. The delivered tidal volume may vary depending on respiratory system impedance and the patient's ventilatory effort. However, BPAP devices are relatively leak tolerant and are thus preferred for use with mask interfaces. Comparisons of volume and pressure preset NPPV have found similar effects on gas exchange and sleep quality. 27, 55 One study found more gastrointestinal side effects from volume preset NPPV. 55 Volume preset NPPV devices may have advantages for individual patients. This document addresses only the use of BPAP devices for delivery of NPPV as these devices are available in sleep centers.
NPPV using BPAP may be delivered in the spontaneous mode (S) in which the patient determines the time spent in IPAP (within the device IPAPtime limits) as well as the respiratory rate. NPPV in the spontaneous-timed (ST) mode provides a backup rate to ensure a minimum respiratory rate (Figure 1) . If the patient fails to initiate an IPAP/EPAP cycle within a time window based on the backup rate, the device will deliver a machine-triggered IPAP cycle for the inspiratory time (IPAP time) set by the prescribing physician. For example, if the back-up rate is 10 bpm, the time window following the previous breath is 6 seconds. If a spontaneous breath does not occur, the device provides a machine triggered breath. In the timed mode (T) the NPPV device delivers IPAP/EPAP cycles at a set respiratory rate with a set inspiratory time. Recently, volume targeted BPAP (VT-BPAP) has been developed in which the IPAP-EPAP difference is automatically adjusted to deliver a target tidal volume. [8] [9] [10] [11] NPPV is often initiated after an attended NPPV titration with PSG. This approach allows determination of an appropriate interface, NPPV mode, IPAP, EPAP, as well as backup rate and inspiratory time (IPAP time), if applicable. IPAP and EPAP can also be adjusted to eliminate obstructive apnea, hypopnea, respiratory effort related arousals (RERAs), and snoring. Some sleep centers use transcutaneous PCO 2 monitoring, end-tidal PCO 2 , or arterial blood gas sampling to guide adjustments to the NPPV device. Monitoring respiratory muscle EMG is performed in some sleep centers to help assess if adequate respiratory muscle rest has been attained during the titration (Figure 2) . A NPPV delivery system consists of three main components: a NPPV device; a mask interface (nasal mask, nasal pillows mask, oronasal mask, or oral interface) held snug to the face by headgear; and a flexible hose that connects the device to the interface. NPPV devices used for titration with PSG also typically provide analog or digital outputs of flow, tidal volume, delivered pressure, and leak (total or unintentional depending on the manufacturer) that may be recorded along with other standard PSG information.
The optimal NPPV device settings may vary widely between patients with various disease processes. NPPV settings may result in variable minute ventilation in the same patient in response to changes in respiratory system impedance, progression of muscle weakness, or alterations in central control due to medications or the underlying disease process. Therefore, and two outside reviewers, the Chair of the AASM Standards of Practice Committee, and the AASM Board of Directors. The AASM Board of Directors approved these recommendations in August 2010.
All members of the Task Force and the Board of Directors completed detailed conflict-of-interest statements; none had Level 1 conflicts relative to the scope of their roles. All participants in the development of this report are directors or active staff members of sleep disorders centers, and all have substantial experience with PAP and NPPV titration. These recommendations should not be considered inclusive of all proper methods of care or exclusive of other methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding the propriety of any specific aspect of care must be made by the clinician in light of the individual circumstances presented by the patient and the availability of diagnostic and treatment options and resources.
The definitions, protocols, procedures, and indications for the diagnosis and management of OSA as specified in the AASM practice parameters for polysomnography 51, 52 and PAP treatment, 53 the AASM Manual for the Scoring of Sleep and Associated Events (i.e., respiratory rules), 54 and the clinical guidelines for titration of positive airway pressure for obstructive sleep apnea should be followed where applicable. 48 
BACKGROUND
Treatment with NPPV via mask has been used effectively in a broad spectrum of disorders with CAH. Many of the initial studies of NPPV used volume ventilators with a mask interface. The volume ventilators were set at relatively high tidal vol- The backup rate is 12, and as the patient did not trigger a breath for 5 seconds, a machine triggered breath was provided (A). Note that spontaneous and machine triggered breaths have similar peak flows (B, C) but different durations and different tidal volumes. The negative pressure spike (A) is an artifact generated by the NPPV device to denote a machine triggered breath.
technologists and clinicians should combine their experience and judgment with the application of these recommendations to attain the best possible titration for any given patient The AASM expects these recommendations to have a positive impact upon the practice of sleep medicine, patient treatment outcomes, and health care costs. These recommendations reflect the state of knowledge at publication and will be reviewed, updated, and revised as new information becomes available. It is important to note that most recommendations published in this report are not practice parameters, since the majority of these recommendations do not achieve the evidence level of typical practice parameters. Instead, most recommendations were developed using the consensus process, and the evidence grading was used only to indicate the level of evidence available to support the recommendations. AASM levels of recommendations ( Table 2 ) are indicated in parentheses after each Task Force recommendation. Recommendations extracted from active AASM practice parameters are labeled "(Standard)" while those not based on published AASM practice parameters are labeled "(Consensus)."
General Recommendations for NPPV Titration PSG Studies in the Sleep Center for Pediatric or Adult Patients with CAH.
Unless otherwise stated it is understood that the recommendations apply to both pediatric and adult patients undergoing NPPV titration with PSG. A flow diagram summarizing the recommendations for NPPV titration is shown in Figure 3. 
4.1.1
The indications, goals of treatment, rationale for use, and side effects of NPPV treatment should be discussed in detail with the patient prior to the NPPV titration study. Careful mask fitting and a period of acclimatization to low pressure before the titration should be included as part of the NPPV protocol.
(Standard A)
This recommendation is based on Standard level recommendation 4.3.4 ("The addition of a systematic educational program is indicated to improve PAP utilization") in the 2006 practice parameters for the use of PAP devices 53 and consensus agreement by the NPPV Titration Task Force. Orientation to the procedure adequate follow-up of the patient during NPPV therapy by a physician knowledgeable in the delivery of NPPV treatment is essential. The recommendations in this report pertain only to nighttime NPPV titration studies. However, some recommendations in this document may be applicable to alternative methods of NPPV titration when under the direction of a physician knowledgeable in NPPV treatment.
RECOMMENDATIONS
The following are recommendations of the NPPV Titration Task Force and the AASM Board of Directors. The scope of these NPPV titration recommendations is restricted to adult and pediatric patients with stable CAH due to NMD, RTCD, CRCD (congenital and acquired), and OHS. Patients with chronic obstructive pulmonary disease, Cheyne-Stokes respiration, and primary central sleep apnea (formerly known as idiopathic central sleep apnea) are excluded. The scope of these NPPV titration recommendations is restricted to pressure preset BPAP ventilation by mask as this is the type of ventilatory support available in most sleep centers. The scope of these NPPV titration recommendations does not address the indications for NPPV treatment. The goal of these NPPV titration guidelines is to outline a practical approach for the titration of NPPV in the sleep center that could be widely available to provide effective NPPV treatment. The titration guidelines do not assert that other careful approaches under knowledgeable physician direction would not constitute acceptable medical care.
The optimal setting for the nocturnal titration of NPPV is in an AASM-accredited sleep center or laboratory with personnel experienced with both NPPV titration and managing patients with hypoventilation such as a registered polysomnography technologist or sleep-trained respiratory therapist. The NPPV titration should be reviewed and treatment pressures selected by a physician board certified in sleep medicine.
It is understood that the recommendations for minimum and maximum IPAP and EPAP may be constrained by the specific BPAP device used during the titration protocol. Lastly, the expectation of the Task Force is that these recommendations should not be followed in a "cookbook" manner; instead, sleep 62 Therefore, it is important to document that NPPV settings selected for chronic treatment are effective in that situation.
Studies in patients with OHS 21 and NMD 63 have documented disturbances in sleep quality due to patient-NPPV device asynchrony. Other studies noted that leak (particularly mouth leak) [64] [65] [66] also resulted in sleep disturbance and reduced the effectiveness of NPPV. Such sleep disturbance and problems with leak would usually not be recognized without PSG. Fanfulla and coworkers 63 found that empiric NPPV settings that were effective and well tolerated during the day were associated with a substantial frequency of ineffective respiratory efforts and worsened sleep quality at night. Guo et al. 21 found that PSG detected periods of patient-NPPV device desynchronization (uncoupling of the onset of the patient's respiratory effort as detected by thoraco-abdominal movement and the onset of an IPAP/EPAP pressure cycle), periodic breathing, or auto-triggering in a group of OHS patients chronically treated with NPPV. Desynchronization was present in 55% of the patients studied and was associated with arousals. These episodes were often not associated with changes in either transcutaneous PCO 2 or oximetry. NPPV titration with PSG or PSG during treatment on the empirically selected NPPV settings would therefore be necessary to identify desynchronization or arousals from leaks. This recommendation is based on consensus of the NPPV titration task force and acknowledges that titration goals may vary based on the individual case characteristics and by CAH etiology. Two published studies documented an improvement in sleep quality with NPPV treatment. 8, 23 If palliation is the main goal, finding a tolerable level of NPPV that improved symptoms (nocturnal dyspnea, morning headache, frequent awakenings) would be the primary goal of NPPV titration and treatment.
Optimal titration of NPPV to decrease the work of breathing during sleep requires monitoring of tidal volume, respiratory rate, and possibly respiratory muscle EMG to document the impact of NPPV. Patients with respiratory muscle weakness often exhibit considerable EMG activity of the accessory muscles of respiration (sternocleidomastoid, scalene, and others) during sleep. 62, [68] [69] [70] In addition, patients with respiratory muscle weakcan improve sleep quality and mask acceptance. 56 The patient should be carefully fitted with an appropriate mask with the goals of minimizing leak, maximizing comfort, and compensating for significant nasal obstruction. The patient should be acclimated to the NPPV equipment (i.e., wearing the interface with the pressure on) prior to "lights off." 48 For pediatric patients behavioral modification techniques may be implemented to increase the tolerability and potential adherence to PAP therapy, [57] [58] [59] since children frequently have problems adjusting to PAP. This recommendation is based on consensus of the NPPV titration task force and is consistent with the recommendations for initiating PAP treatment in patients with OSA. Several studies documenting the effectiveness of NPPV in CAH syndromes used titration with PSG to determine the NPPV settings. These include studies in patients with NMD 40, 42, 44 and OHS. 13, 14, 21, 22 In most of the studies, the titration protocols were not presented in detail. However, the stated goals of titration usually were to eliminate obstructive events and improve ventilation such that the SpO 2 was > 90% and the transcutaneous PCO 2 was less than a set goal (such as 45 to 50 mm Hg), if sufficient pressure to achieve these goals was tolerated.
NPPV treatment can be initiated without PSG. 3, 4 In some situations, based on clinical judgment, treatment can be empirically initiated at low pressure settings. Treatment pressures are then increased as tolerated over days to weeks based on daytime PCO 2 measurements, nocturnal oximetry, subjective relief of symptoms, and in some cases nocturnal transcutaneous PCO 2 monitoring. Such an approach may be suitable when the patient has difficulty tolerating NPPV or the major treatment goal is palliation. Several of the studies documenting the efficacy of NPPV titration in CAH syndromes did not use PSG for NPPV titration. NPPV treatment was initiated in RTCD, [24] [25] [26] [27] [28] 30 NMD, 3, 26, 39 and OHS 12 patients without PSG for titration. Many of these studies actually admitted patients to the hospital for NPPV treatment initiation (Appendix). In most settings today, hospital admission for NPPV titration alone would not be financially feasible or considered as medically necessary. A randomized trial of inpatient versus outpatient initiation of home mechanical ventilation in patients with nocturnal hypoventilation found equivalent outcomes. 60 However, the patients did not have diurnal hypoventilation at baseline and PSG was not used to establish effectiveness of treatment. Outpatient initiation of NPPV without a PSG titration requires an experienced team of providers (physicians and respiratory therapists) as well as systematic approach to intervene for initial problems and for careful follow-up.
Attended NPPV titration with PSG has a number of advantages. 61 These include documentation of the effects of NPPV on sleep quality, obstructive apnea and hypopnea, ventilation, to hypoventilate after upper airway patency is restored. 13, 17 In such patients BPAP (NPPV) has been proven effective and by augmenting ventilation may prevent the need for mechanical ventilation or supplemental oxygen.
12-21 A recent randomized trial 22 compared CPAP and BPAP for treatment of patients with OHS. Patients with significant residual desaturation (SpO 2 < 80% for > 10 min) on a level of CPAP that eliminated obstructive events, an acute rise in PCO 2 > 10 mm Hg during REM sleep, or an increase in PCO 2 > 10 mm Hg in the morning compared to the afternoon were excluded. An equivalent reduction in daytime PCO 2 was noted at 3 months in patient randomized to CPAP or BPAP. Adherence to the treatment modalities was also not significantly different. In the BPAP group the mean IPAP and EPAP levels used were 16 and 10 cm H 2 O, respectively, and the spontaneous mode of BPAP was employed. A few patients in both groups required supplemental oxygen in addition to PAP. Of note, the most severe OHS patients were excluded from this study and were treated with NPPV outside of the study protocol. OHS patients may require high levels of EPAP to prevent obstructive apnea and this tends to limit the available range of pressure support unless very high IPAP levels are used. In a study of the effect of NPPV in OHS patients by Berger and coworkers, 13 
Attended NPPV titration with polysomnography is the recommended method to identify an effective level of ventilatory support for patients with RTCD in whom NPPV treatment is indicated. (Level A -Consensus)
This recommendation is based on consensus of the NPPV titration task force. Several studies have documented an improvement in quality of life and gas exchange in patients with RTCD. To date, most published studies concerning NPPV treatment in RTCD patients [23] [24] [25] have not used an attended NPPV titration study to select levels of pressure. However, in one study 24 patients were admitted to the hospital for initiation of NPPV. Treatment NPPV settings were based on daytime arterial blood gas testing, nocturnal oximetry, or nocturnal transcutaneous PCO 2 monitoring. One study also used nocturnal monitoring of arterial blood gases. 25 In this study, the mean IPAP and EPAP values were 21.1 and 3.1 cm H 2 O, respectively, with a backup rate of 20 bpm. In this study improvement in daytime PCO 2 was correlated with the amount of pressure support. A study by Gonzalez and coworkers 24 used a mean backup rate of 15 bpm.
Attended NPPV titration with polysomnography should be performed before NPPV treatment in patients with acquired or congenital CRCD when NPPV treatment is deemed indicated. (Level A -Consensus)
This recommendation is based on consensus of the NPPV titration task force. Some patients with CRCD such as those with congenital central hypoventilation may have life-threatening events if not adequately ventilated during sleep. In these patients, documentation of the adequacy of NPPV treatment settings is essential before chronic NPPV treatment can be safely initiated. Patients with congenital central hypoventilation often require tracheostomy and volume ventilation from birth at least during sleep. Those patients who do not require daytime ness or increased work of breathing often have a pattern of rapid shallow breathing (low tidal volume, high respiratory rate). Evidence that NPPV has reduced work of breathing includes an increase in tidal volume, a reduction in respiratory rate, [71] [72] [73] and absence or reduction of inspiratory EMG activity of the muscle of respiration compared to baseline levels or those on lower amounts of NPPV support 68 ( Figure 2) . Evidence of reduced work of breathing as just described, or by other validated methods, in the course of NPPV titration serves as the metric of successful NPPV titration where respiratory muscle rest during sleep is desirable.
During attended NPPV titration gas exchange can be monitored by pulse oximetry and the arterial PCO 2 may be measured intermittently by arterial blood gas testing or continuously estimated by transcutaneous PCO 2 or end-tidal PCO 2 monitoring to allow precise documentation of an adequate level of NPPV support. This recommendation is based on the Standard recommendation in the practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders and the consensus based AASM Clinical Guidelines for PAP titration in patients with Obstructive Sleep Apnea. 48 The majority of patients with the obesity hypoventilation syndrome 12 have discrete apneas and hypopneas. In addition, several studies of patients with chronic hypoventilation due to chest wall disorders and neuromuscular disorders also were found to have obstructive respiratory events during PSG. For example, in one study by Gonzalez and coworkers 24 of patients with kyphoscoliosis the AHI averaged 13.9 events/hour. While concurrent OSA may be suspected in candidates for NPPV who report snoring and witnessed apnea, absence of these symptoms does not rule out significant obstructive events.
In instances

Attended NPPV titration with polysomnography is the standard method to identify optimal treatment pressure settings for patients with the OHS in whom NPPV treatment is indicated (Level A -Consensus).
This recommendation is based on the AASM Practice Parameters for PSG and the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders. 53 The majority of patients with OHS have obstructive sleep apnea. 9, 10, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] However, a minority simply have daytime hypoventilation that worsens during sleep in the absence of discrete obstructive events. 18 This NPPV titration recommendation does not imply that CPAP may not be effective in preventing apnea, hypopnea, and snoring in individual OHS patients. Chronic CPAP treatment in OHS patients can also result in a reduction in daytime PCO 2 in some patients. 13 However, many OHS patients require high levels of CPAP and may manifest residual arterial oxygen desaturation or continue This recommendation is based on consensus of the NPPV titration task force. Patients with OHS may not require a backup rate. However, patients with severely defective central control of ventilatory drive often require a backup rate to prevent central apneas and/or hypoventilation. In patients with respiratory muscle weakness or decreased respiratory system compliance, feeble inspiratory efforts may fail to reliably trigger an IPAP/ EPAP cycle; such patients often benefit from a backup rate. The timed mode is infrequently used in sleep centers. However, there are individual patients who are more adequately treated with the timed mode than the ST mode. The timed mode employing a set respiratory rate that is typical higher than the native rate may result in a more stable pattern of ventilation in some patients. Parreira and coworkers 76 compared the spontaneous and timed modes in normal subjects awake and asleep. Using the timed mode, they were able to deliver higher minute ventilation at lower IPAP than with the spontaneous mode and the patient's sleeping breathing rate. Of note, a relatively high respiratory rate of 20 was used in the timed mode, with an inspiratory/expiratory ratio of 1 to 2. These findings may not generalize to patients with hypoventilation but illustrate the point that the timed mode or the ST mode with a relatively high rate is an option that could be tried in patients who do not tolerate high IPAP or in whom the maximally tolerated pressure support at the spontaneous respiratory rate does not deliver adequate minute ventilation. This may be a particularly effective strategy in patients with RTCD and reduced respiratory system compliance, in whom a high PS may be required to augment tidal volume. ventilation may be transitioned to NPPV if they are motivated, found to be reliably adherent, and a sleep study documents efficacy of NPPV. [32] [33] [34] Often the transition to NPPV occurs when the patient attains an age sufficient to accept mask ventilation. However, selected patients have used NPPV from a very early age. A potential complication of early use of mask ventilation is development of central facial hypoplasia, 74, 75 possibly due to chronic mask pressure. This is most likely to occur in patients needing mask ventilation during the day as well as during sleep.
Recommendations for parameters that
Attended NPPV titration with polysomnography allows definitive identification of an adequate level of ventilatory support for patients with NMD in whom NPPV treatment is planned. (Level A -Consensus)
This statement is based on consensus of the NPPV task Force. Numerous studies have demonstrated benefits in patients with NMD although the benefits may vary depending on the specific disorder. 3, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] Attended NPPV titration with PSG in NMD patients can provide rapid determination of an adequate level of support, intervention for obstructive sleep apnea if present, and documentation of the effectiveness of the chosen NPPV settings in various sleep stages and body positions. Interventions for mask and leak problems can be made quickly. A number of studies in NMD patients did employ NPPV titration with PSG. 40, 42, 44 It is acknowledged that some centers with considerable expertise in treating patients with NMD (e.g., ALS) have a structured program for initiating NPPV on an outpatient basis during the daytime. NMD patients are often started on BPAP at low pressures (IPAP = 8, EPAP = 4) after a period of daytime adaptation under direct supervision. If patients tolerate nocturnal NPPV with low pressures, the settings are increased over weeks to months based on symptoms and/or daytime arterial PCO 2 measurement (or estimates of arterial PCO 2 such as end-tidal PCO 2 ). In one study of this approach in ALS patients, 36 symptom relief was provided in 4 of 18 patients with the low initial settings, while most other patients required either one or two increases in pressure. Only 6/19 required a pressure support over 10 cm H 2 O. In patients with rapidly progressive NMD, the main goal of treatment is often palliation of symptoms and improvement in quality of life rather than normalization of nocturnal arterial PCO 2 .
In a randomized controlled study of the effect of BPAP in the ST mode on survival and quality of life in ALS, 3 the average IPAP and EPAP settings were 15 and 6 cm H 2 O, respectively. In this study only the subgroup of ALS patients without moderate to severe bulbar dysfunction had improved survival. However, all patients treated with NPPV had improvement in the quality of life. Patients with bulbar involvement may have more difficulty tolerating NPPV and mask ventilation. These patients may also have a greater risk of aspiration than those without upper airway dysfunction. is partitioned into a bias portion (leak) and a variable portion (patient flow). The leak is composed of the intentional leak + unintentional leak (mask or mouth leak). The intentional leak is due to flow through the non-rebreathing orifice. This leak depends on the interface type and delivered pressure. In some NPPV devices, the leak signal reflects the total leak; in others, a mask interface can be specified and the leak signal reflects unintentional leak. Several studies have documented that leak, especially mouth leak, can impair the effectiveness of NPPV and sleep quality. [64] [65] [66] [67] As delivered pressure increases during the titration, the total leak will increase. Therefore, what constitutes an inappropriately high leak will depend on interface and pressure (see also 4.8.6). Some sleep centers with considerable experience in NPPV titration in patients with muscle weakness routinely record surface EMG from respiratory muscles using bipolar electrodes with techniques similar to those used for recording the anterior tibialis EMG. Surface diaphragm EMG recording utilizes two electrodes about 2 cm apart horizontally in the seventh and eighth intercostal spaces in the right anterior axillary line. 68, 70 The right side of the body is used to reduce EKG artifact. Other sites include the sternocleidomastoid (an accessory muscle of respiration) and the right parasternal intercostal muscle (2nd and 3rd intercostal spaces in the mid-clavicular line). In normal individuals, the accessory muscles are usually quiet during sleep except during periods following arousal. Inspiratory EMG activity is noted in the intercostal muscles and the diaphragm during NREM sleep. During REM sleep, the intercostal activity is inhibited but diaphragmatic activity persists (although frequently diminished during bursts of eye movements). In contrast, in patients with respiratory muscle weakness or increased work of breathing, the EMG of accessory muscles often shows inspiratory activity during NREM sleep. During the NPPV titration, a reduction in the EMG activity of respiratory muscles (accessory, intercostals, diaphragm) may be a useful indicator that sufficient pressure support is being administered to allow muscle rest (Figure 2) . 4 Determination of the arterial PCO 2 by arterial blood gas sampling is the gold standard but is invasive, and arterial blood gas sampling requires special expertise. In addition, rapid access to a laboratory where the sample can be processed may be prob-NPPV devices designed for titration during polysomnography generate a digital or analog flow signal based on accurate flow sensors within the device. The majority also provide signals reflecting an estimate of leak and tidal volume as well as the delivered pressure. During NPPV titrations, the use of a standard nasal pressure sensor placed under the nares is problematic due to the difficulty in obtaining a good PAP mask seal, since the tubing must pass underneath the mask to reach the nares. The use of thermal devices under the mask is also not recommended, as the signal is not proportional to airflow. The flow output from most NPPV devices while accurate for assessing airflow and flow limitation is often too filtered or undersampled to display snoring. This recommendation is based on consensus of the NPPV titration task force. While the flow signal readily allows detection of apnea and hypopnea, it may be more difficult to visually estimate a tidal volume that depends on both the inspiratory time was well as flow amplitude. Devices used for NPPV titration in sleep centers generally provide an analog or digital output of the estimated tidal volume derived from integration of the flow signal produced by an accurate flow sensor in the device. A breath-by-breath estimate of tidal volume is almost always available for display in the software or on the peripheral device remotely controlling the NPPV device. However, recording the tidal volume signal (Figure 1) clearly show trends and variation during acquisition and may benefit the physician reviewing the study. The product of the estimated tidal volume and respiratory rate provides an estimate of the minute ventilation. Recording of delivered pressure is helpful to the technologist and physician reviewing the sleep recording. The pressure signal clearly shows the IPAP/EPAP cycle and is especially helpful in determining the pattern of response of the NPPV device in situations where the backup rate frequently intervenes. Some NPPV devices output a brief signal (intentional artifact) before each machine triggered breath (Figure 1) . Another method to identify machine triggered breaths is to observe that they often have a different inspiratory time than spontaneous breaths. (level a -consensus).
Recording of estimates of leak is helpful to the technologist and the physician reviewing the sleep recording. The total flow adult patients during diagnostic polysomnography. However, gas was sampled from a mask covering the nose and mouth rather than the nares. In contrast Kirk and coworkers 81 found reasonable agreement between end-tidal PCO 2 and transcutaneous PCO 2 during pediatric polysomnography. In the commonly used side-stream capnography method, exhaled gas is suctioned via a nasal cannula to an external CO 2 sensor. The major challenge for end-tidal PCO 2 monitoring during NPPV titration is dilution of the exhaled sample by flow from the NPPV device (especially if gas is sampled at the mask). One approach is to have the patient wear a sampling nasal cannula under the NPPV mask interface. Using this approach gas is sampled as it is exhaled from the nares rather than suctioned from the mask. A similar method was used by Parreira and coworkers 76 during their study of bilevel PAP in normal subjects. A disadvantage of this approach is that the presence of the cannula passing under the nasal or oronasal mask seal could cause excessive leak. If an oral mask is used the sampling catheter would be directly connected to the mask. Recommendations 4.2.2.9.1 and 4.2.2.9.2 are based on consensus of the NPPV titration task force and are consistent with the AASM clinical guidelines for the manual titration of positive airway pressure in patients with obstructive sleep apnea. 48 As mentioned in an earlier section, pediatric patients require an introduction to masks prior to the NPPV titration. A Child Life Specialist is an example of a trained professional with expertise in helping children and their families overcome challenging life events in the medical setting. A Child Life Specialist or similar professional with expertise in child development can help children and their families adapt to masks and NPPV titration.
heAted humidificAtion should be AvAilAble for PAtients undergoing nPPv titrAtion. the Addition of humidificAtion is indicAted if the PAtient comPlAins of significAnt orAl or nAsAl dryness (unless humidificAtion is not tolerAted by the PAtient). (level A -consensus)
This recommendation is based on consensus of the task force. It is consistent with clinical guidelines for the manual titration of CPAP and BPAP in patients with OSA. The AASM Stanlematic for sleep centers located outside of hospital. In pediatric patients, sampling of a capillary blood gas (arterialized blood) is often used as an alternative to arterial blood gas testing. Another limitation of arterial blood gas monitoring is that serial testing during sleep requires either an indwelling catheter or repeated arterial punctures, and obtaining a sample may well cause arousal and a change in the PCO 2 . This recommendation is based on consensus of the NPPV titration task force. We know of no published study that documents the accuracy of monitoring end-tidal PCO 2 during NPPV titration. Of note, Sanders and coworkers 80 found poor agreement between end-tidal PCO 2 and arterial blood gas testing in Budweiser and coworkers 25 This recommendation is based on consensus agreement by the NPPV titration task force.
The maximum IPAP available on most NPPV devices is 25 or 30 cm H 2 O. A lower value for the maximum IPAP was recommended for patients less than 12 years of age in the clinical guidelines for manual titration of PAP in patients with OSA. 48 It is acknowledged that individual patients may benefit from higher IPAP. High pressure levels are problematic for obtaining an adequate mask seal and often require significant mask tightening. There have been reports of changes in facial structure associated with NPPV in children. 74, 75 Although it is not known whether the interface itself or the pressure delivered is the issue, it seems prudent to avoid very high pressures if possible in children.
The minimum and maximum incremental changes in PS during NPPV titration should be 1 and 2 cm H 2 O, respectively. (Level A -Consensus).
This recommendation is based on consensus agreement by the NPPV titration task force.
Although smaller pressure changes than 1 cm H 2 O are possible, such changes are unlikely to be clinically meaningful. A maximum incremental change of 2 cm H 2 O is recommended to avoid over titration. Recommendation 4.4.1 is based on a consensus of the NPPV titration task force and is consistent with the AASM clinical guidelines for PAP titration in patients with OSA. 48 These guidelines provide a protocol for increasing in the IPAP and EPAP to eliminate obstructive apneas, hypopneas, RERAs, and snoring.
Recommendations for the Adjustment of Pressure
Recommendations for adjusting pressure support for low tidal volume or hypoventilation during sleep
4.4.2.1 the ps should be increased every 5 minutes if the tidal volume is below the acceptable goal. an acceptable tidal volume goal for most patients ranges from 6 to 8 ml/kg using ideal body weight (Figure 3). (level a -consensus) .
Recommendation 4.4.2.1 is based on consensus of the NPPV titration task force. An acceptable tidal volume may vary with the disorder being treated and the respiratory rate. Tidal volumes of 6 to 8 mL/kg at typical respiratory rates usually dedards of Practice for CPAP and BPAP treatment also states "the addition of heated humidification is indicated to improve PAP utilization." 53 Two controlled studies were not able to document an improvement in patient acceptance of CPAP treatment with the prophylactic use of heated humidity. 82, 83 However, the level of CPAP was relatively low (around 10 cm H 2 O) and the nasal symptoms were mild in one study. NPPV treatment frequently uses relatively high pressures and is associated with high intentional and unintentional leak. A bench study documented that NPPV devices deliver air at a reduced relative humidity compared to ambient air and that increasing IPAP lowered the delivered relative humidity. 84 Nava and coworkers compared heated humidification with a heat and moisture exchanger using a crossover protocol and found similar adherence to NPPV. 85 However, most patients preferred heated humidity. Tuggey and coworkers 66 found that heated humidification reduced the impact of mouth leak on nasal resistance (increased with mouth leak) and delivered tidal volume in a group of normal subjects breathing on NPPV during the day. Initiation of humidification at the start of a NPPV titration PSG may be useful in selected patients with significant nasal congestion or a history of severe mucosal dryness during sleep, or in particularly dry climates such as the American southwest or during the winter in cold climates. At the minimum, heated humidity should be available for patients who develop severe nasal congestion or dryness during the night.
Recommendations for Initial and Maximum Pressures during NPPV Titration
The recommended minimum starting IPAP and EPAP should be 8 cm H 2 O and 4 cm H 2 O, respectively. (Level AConsensus).
This recommendation is based on consensus agreement by the NPPV PAP Titration Task Force An EPAP of 4 cm H 2 O is the lowest available on most NPPV devices. The recommendation of a starting IPAP is based on the minimum recommended pressure support. These recommendations are consistent with the AASM Clinical Guidelines for the manual titration of PAP in patients with OSA. 
The recommended minimum starting pressure support (difference between IPAP and EPAP) should be 4 cm H 2 O. (Level A -Consensus)
This recommendation is based on consensus agreement by the NPPV Titration Task Force.
While it is acknowledged that 4 cm H 2 O provides only a modest degree of pressure support, starting at this level will allow adaptation to positive airway pressure.
The recommended maximum pressure support (difference between IPAP and EPAP) should be 20 cm H 2 O. (Level A -Consensus)
In the AASM clinical guidelines for titration of CPAP and BPAP, the recommended minimum IPAP-EPAP difference was 4 cm H 2 O and the maximum was 10 cm H 2 O. However, in the case of OSA, the major objective is to maintain airway patency.
Best Clinical Practices for the Sleep Center Adjustment of NPPV 4.4.2.5 pressure support may be increased if respiratory muscle rest has not been achieved by nppv treatment at the current settings for 10 minutes of more. adequate respiratory muscle rest during nppv is associated with resolution or improvement in tachypnea and/or excessive inspiratory effort as measured by phasic emg activity of inspiratory muscles (Figure 3 
). (level a -consensus)
This recommendation is based on consensus of the NPPV titration task force. As noted in a previous section, the accessory muscles of respiration are not normally active during sleep. The absence or decrease in accessory muscle EMG and a decrease in intercostal and diaphragmatic EMG would suggest that a given level of NPPV was providing respiratory muscle rest.
4.4.2.6 pressure support may be increased if the spo 2 remains below 90% for 5 minutes or more and tidal volume is low (< 6 to 8 ml/kg). if discrete obstructive apneas or hypopneas are present, the clinical guidelines for pap titration in osa patients should be followed. (level a -consensus).
This recommendation is based on consensus of the NPPV titration task force. The rationale behind this recommendation is that an increase in pressure support may increase tidal volume and reduce or eliminate residual hypoventilation thereby improving oxygenation. If not successful the addition of supplemental oxygen may be needed. While criteria for chronic oxygen therapy often use a SpO 2 of less than 88% as an indication for supplemental oxygen, the slightly higher goal of 90% was chosen to allow for a margin error as the tidal volume associated with a level of pressure support could vary somewhat with the clinical condition of the patient. In addition, in some circumstances the pulse oximetry values can overestimate the actual arterial oxyhemoglobin saturation. Recommendations 4.5.1 and 4.5.2 are based on consensus of the task force and the fact that patients with central hypoventilation by definition may fail to trigger an IPAP/EPAP cycle for an inappropriately long period (central apnea) or may have an inappropriately low respiratory rate to provide adequate minute ventilation. In addition, many patients with disorders such as central congenital hypoventilation will not respond to worsening hypoxemia with an increase in respiratory effort. Other patients with CAH may unreliably trigger IPAP/EPAP cycle due liver normal minute ventilation. In patients with hypercapnia, a small increase or decrease in alveolar ventilation results in a relatively large decrease or increase in the PCO 2 due to the hyperbolic relationship between the two variables. If lung disease is present, a higher minute ventilation is needed to deliver adequate alveolar ventilation due to an increase in physiological dead space. In normal individuals, the dead space is approximately equal to 2 mL/kg. The recommended tidal volume target for volume targeted BPAP is 8 mL/kg using ideal body weight. [8] [9] [10] Slightly lower tidal volumes with higher respiratory rates may be better tolerated in individual patients (particularly in RTCD). It should also be noted that a reduction in leak by mask refit or change may improve the effectiveness of the current PS. Therefore, intervention for leak should be considered especially if prior increases in PS have been ineffective with respect to increasing tidal volume. 65, 66 The accuracy of NPPV device estimates of tidal volume is dependent on the accuracy of the flow signal. If the accuracy of the flow signal is degraded by mouth leak (nasal mask) or high mask leak, then the estimated tidal volume may not accurately reflect the tidal volume of the patient. Discrepancy between device estimates of tidal volume and the clinical scenario (including other related sensors) should prompt the technologist to check for excessive leak. As an example, increases in the pressure support (difference between IPAP and EPAP) that fail to raise tidal volume might herald excessive leak. 2 remains 10 mm hg above goal at the current settings for 10 minutes or more. an acceptable goal for pco 2 is a value less than or equal to the awake pco 2 (Figure 3) . (level a -consensus).
Recommendations for the Use of ST and Timed Modes
the ps should be increased if the arterial pco
4.4.2.
3 the ps should be increased in 1 to 2 cm h 2 o increments if the transcutaneous pco 2 or end-tidal pco 2 remains 10 mm hg or more above goal for 10 minutes or more. this assumes that these measurements of the pco 2 have been documented to accurately reflect the arterial pco 2 in a given patient (Figure 3) . (level a -consensus). It is acknowledged that not all sleep centers have the ability to measure transcutaneous or end-tidal CO 2 or the expertise to use the information. This recommendation is included for sleep centers who have the capability to make these measurements and routinely use them during NPPV titrations. Several of the studies included in the Appendix did utilize measurements of CO 2 to guide NPPV titration. It should be noted that in normal subjects there is a small increase in arterial PCO 2 during sleep of about 5 to 10 mm Hg. However, as most patients being treated with NPPV have daytime hypoventilation, one ideal goal of treatment would consist of preventing a further increase in the arterial PCO 2 during sleep. The daytime awake PCO 2 may decrease with chronic nocturnal NPPV treatment in a substantial number of patients with CAH. Thus, the level of nocturnal PCO 2 on NPPV may eventually be lower than the initial goal. On the other hand some patients may not initially tolerate a level of PS adequate to meet the chosen PCO 2 goal. However, both daytime and nocturnal PCO 2 may decrease over time with chronic NPPV treatment.
per minute, no more frequently than every 10 minutes, if the desired goal of the backup rate (or fixed respiratory rate) is not attained with lower rates (Figure 3). (level a -consensus These recommendations (4.5.4.1 to 4.5.4.3) are based on consensus of the NPPV titration task force and review of industry protocols. In a study of NMD patients Katz and coworkers 44 used a back-up rate 10% below that patient's resting breathing rate. One industry protocol suggests starting at a minimum rate of 8 to 10 breaths per minute or 2 breaths per minute below the patient's resting rate. 86 Gonzalez and coworkers 24 used a backup rate of 15 in a group of patients with RTCD. Mellies et al. 42 used backup rates ranging from 14 to 24 (mean 19.6) in a group of children with NMDs. Tuggey et al. 27 used a mean backup rate of 15 in a study of NPPV and patients with RTCD, while another study 25 used a backup rate of 20 breaths per minute in a similar population.
Recommendations for choice of the inspiratory time in the ST and timed modes
4.5.5.1 the initial inspiratory time (ipap time) for machinetriggered breaths in the st mode or all breaths in the timed mode is chosen based on the respiratory rate and the need to provide both an adequate tidal volume and an appropriate inspiratory time to expiratory time ratio (i: e ratio). another method of expressing the i: e ratio is the %ipap time which is inspiratory time (ipap time) as a % of the cycle time ( The recommendations 4.5.5.1 to 4.5.5.3 are based on consensus agreement by the NPPV titration task force. When NPPV devices are used in the ST mode both the respiratory rate and the duration of IPAP (inspiratory time or IPAP time) for machine triggered breaths must be specified (although the devices do have default values). Specifying the respiratory rate specifies the cycle time (60 sec/respiratory rate in breaths per minute). As the respiratory rate increases the maximum IPAP time decreases for a given inspiratory/expiratory ratio (I/E ratio). A convenient method is to specify the %IPAP time (IPAPtime X 100 / cycle time). In general the minimum recommended I:E to muscle weakness or develop central apnea during the NPPV titration. Given the fact that muscle strength may vary over time in patients with NMD, most clinicians would use a backup rate for chronic treatment in these patients even if not required during the NPPV titration. Several of the studies reviewed employed the ST mode in NMD, 3, 39, 44 OHS, 18 and RTCD. This recommendation is based on consensus of the task force. Using a higher respiratory rate can potentially deliver higher minute ventilation with the same tidal volume. However, at higher rates, the time for exhalation decreases. Choice of respiratory rate and inspiratory time are discussed below. AVAPS (both in the ST mode) using a randomized crossover trial in patients with the obesity hypoventilation syndrome. AVAPS resulted in a slightly higher ventilation and lower PCO 2 without any better sleep quality or quality of life measures compared to BPAP ST. Using the same device, Ambrosio and coworkers 9 studied an assortment of patients with CAH who were stable on BPAP support. A validation night preceded the study nights to ensure the BPAP settings were adequate and to provide guidance for the AVAPS settings. Patients then were studied on BPAP or AVAPS in random order. On AVAPS the minute ventilation was greater than BPAP, but sleep quality was comparable between the two NPPV modes. Using a different VT-BPAP device, Janssens et al. 10 monitored patients with an obesity hypoventilation syndrome using either BPAP or VT-BPAP for one night each in random order. Sleep quality was worse but nocturnal PtcCO 2 slightly lower on VT-BPAP. It is possible that patients might have exhibited better sleep quality after a longer period of adaptation to the VT-BPAP. Jaye and coworkers 11 compared BPAP ST with an autotitrating bilevel ventilator (AutoVPAP) in patients with stable neuromuscular and chest wall disease and nocturnal hypoventilation and found AutoVPAP to produce comparable control of nocturnal oxygenation without compromising sleep quality. The mean nocturnal transcutaneous PCO 2 was higher with AutoVPAP although the difference was unlikely to be clinically significant. AutoVPAP (ResMed, Poway, CA) is not currently available in the United States. These studies suggest VT-BPAP can be effective, but the role of VT-BPAP in the NPPV treatment of patients with CAH remains to be determined. 48 Recommendation 4.7.2 is made with the understanding that pulse ratio is 1:2, with longer exhalation recommended for patients with obstructive lung disease. The relationship of the respiratory rate, the %IPAPtime and the IPAP time are illustrated in Table 3 . At a respiratory rate of 15 breaths per minute, the range of inspiratory time corresponding to 30% to 40% (%IPAP time) is 1.2 to 1.6 seconds.
Recommendations for choosing the backup rate in the ST
Recommendations for the Addition of
The timed mode is rarely used in most sleep centers but is an option in patients unable to synchronize with the NPPV device or those with consistently feeble respiratory efforts during sleep. In this mode, one specifies the respiratory rate and the inspiratory time for all breaths.
A lower %IPAP time and I:E ratio is desirable in patients with obstructive airway disease to allow a sufficient expiratory time as expiratory airflow is reduced in these patients. A greater %IPAP time (greater I:E ratio) is preferred in patients with restrictive lung disease to allow for a longer inspiratory time. As the respiratory rate becomes faster, the inspiratory time must be decreased to maintain an adequate I:E ratio. Recommendation 4.8.4 is based on consensus agreement by the NPPV titration task force. NPPV devices transition from IPAP to EPAP during a patient triggered breath when flow falls below a set value. In patients with a stiff chest wall (decreased compliance), flow rates may fall as the maximum inspiratory volume is approached. An early fall in the absolute flow rates may trigger the transition to EPAP prematurely. Certain devices provide a minimum IPAPtime to ensure that IPAP lasts long enough to allow delivery of an adequate tidal volume. In situations of high leak (continued flow) or muscle weakness, the IPAP to EPAP transition may be unduly delayed. A default maximum IPAP duration of 3 seconds exists on some devices, while in other devices a shorter maximal IPAP time may be chosen.
Recommendations for the
4.8.5
During the NPPV titration, mask refit, adjustment, or change in mask type should be performed whenever any significant unintentional leak is observed or the patient complains of mask discomfort. If mouth leak is present and is causing significant symptoms (arousals) use of an oronasal mask or chin strap can be tried. (Level A -Consensus) 4.8.6 In general, an unacceptable leak for NPPV at a given IPAP/EPAP is one that is significantly higher than the leak resulting from a given mask fitted securely in place at the current pressure settings. The expected value of leak will depend on the pressures, specific interface, and NPPV device (whether total or unintentional leak information is provided) as specified by the manufacturer. (Level A -Consensus)
The recommendations 4.8.5 and 4.8.6 are based on consensus agreement by the NPPV Titration Task Force and are consistent with the recommendations concerning leak in the Clinical Guidelines for Titration of PAP in patients with OSA. 48 The total leak is equal to the sum of the intentional leak (required to prevent rebreathing) and unintentional leak (mask and/or mouth leak depending on whether a nasal or full face mask is being used). The intentional leak depends on the specific interface and the level of pressure. Intentional leak can be appreciable with most interfaces at high pressure. NPPV devices used in sleep centers provide an estimate of leak. Some devices allow specification of an interface type and adjust the reported leak values accordingly. The trend in leak is often more informative than the absolute leak value. For example, a sudden increase in leak with minor or no changes in treatment pressure is a hint that an increase in unintentional leak has occurred. Mask leak may be minimized by mask refit or readjustment and/or switch to another mask type. If mouth leak is suspected, use oximetry can overestimate the actual arterial oxyhemoglobin saturation in some circumstances and that the effective inspired oxygen concentration can fall if machine flow increases due to higher leak. [87] [88] [89] [90] A slightly higher goal than 88% (90%-94%) might be prudent in some circumstances. Of note, since the intentional leak increases with the magnitudes of either IPAP or EPAP, the effective fraction of oxygen in the inspired air (FiO 2 ) for a given supplemental oxygen flow rate (bleed in) falls as these pressures increase. [87] [88] [89] [90] The FiO 2 does not appear to vary with the amount of PS or the respiratory rate. Recommendation 4.7.4 is based on several studies of models that evaluated the optimal location at which supplemental oxygen should be connected to the NPPV circuit. A 3-orifice "T" shaped connector attached between the NPPV device outlet and the hose allows for the addition of supplemental oxygen into the circuit through the side arm of the T connector. The results of these studies varied somewhat possibly due to the position at which the FiO2 was sampled. One study found the best location to be at the NPPV outlet assuming the leak port was in the mask, 89 while another found a connection midway between the machine and the exhalation valve 87 was optimal. The latter attachment is not practical in most settings. In any case, an attachment position allowing adequate mixing and one providing a reservoir of enriched gas for inspiration appears to optimize the FiO 2 for a given supplemental oxygen flow and level of BPAP. Recommendations 4.8.1 and 4.8.2 are based on consensus agreement by the NPPV titration task Force. Recommendation 4.8.1 is consistent with the AASM guidelines for titration of CPAP and BPAP in sleep apnea patients. 48 Regarding 4.8.2, there is currently no evidence to support the use of pressure relief BPAP. To date, there is conflicting evidence about the ability of flexible CPAP to improve adherence. 91, 92 However, some patients may find flexible BPAP more comfortable. Pressure relief BPAP is available only in the spontaneous mode.
Recommendations Concerning Patient Comfort and Leak
4.8.3
The rise time (time duration for pressure change from EPAP to set IPAP) should be increased or decreased for patient comfort. Patients with obstructive airway disease often prefer shorter rise times (100 ms to 400 ms) and patients with restrictive disease (NMD, RTCD) patients often prefer longer rise times (300 ms to 600 ms). A rise time of approximately PAP titration in patients with OSA. 48 This scheme was based on grading criteria proposed by Hirshkowitz and Sharafkhaneh. 93 It is acknowledged that the above grading scheme may not be relevant for all patients and must be individualized. For example, if the major goal of NPPV treatment is palliation, an optimal titration may well consist of NPPV settings that significantly improve patient comfort. Finally, since the technologies used for assessment of ventilation and/or respiratory muscle activity varies considerably among sleep laboratories, the task force offers solely what it deemed reasonable treatment goals for said parameters. Adequacy in these parameters should be defined individually by each sleep laboratory. Recommendations 4.9.3.1 and 4.9.3.2 are based on consensus of the task force and are consistent with recommendations made in the clinical guidelines for titration of CPAP and BPAP in patients with OSA. 48 Minimal information is available concerning adherence to NPPV treatment except for patients of a chin strap or switch to a full face mask may be beneficial. Mouth leak is a significant problem in patients on NPPV treatment and may cause arousals even if the NPPV device is able to maintain the desired IPAP and EPAP. [64] [65] [66] Teschler and coworkers 65 studied a group of patient being treated with nasal BPAP who complained of symptomatic mouth leak. Taping the mouth substantially reduced arousals and increased the amount of REM sleep. Substantial mouth leak is often associated with complaints of oral dryness that may persist despite the use of heated humidification.
Indications for repeating an NPPV titration
Although BPAP devices are leak tolerant, high leak can reduce the ability of a given pressure support setting to augment tidal volume. 65, 66 If tidal volume is inadequate and leak relatively high, interventions to reduce leak may improve tidal volume without requiring an increase in pressure support. The recommendations 4.9.1.1 to 4.9.1.5 are based on consensus of the NPPV titration task force and are similar to the grading of an adequate PAP titration in the clinical guidelines for with the OHS. As BPAP at fixed settings does not deliver a set tidal volume, pressure settings determined during a NPPV titration may not remain adequate if patient characteristics such as muscle strength change during chronic treatment. In addition, concurrent medical problems or medications might impact the effectiveness of treatment. This recommendation is based on consensus of the task force and recognizes the fact that the clinical condition of patients may change (weight gain, reduction in muscle strength, progression of the underlying cause of CAH), with the result that current NPPV treatment may no longer be adequate. The assessment of oxygenation and ventilation in such cases is typically carried out during quiet breathing while awake and at rest. Continues on following page
Recommendations for
